-
Vivos Therapeutics raises $4.64 million from warrant exercises
-
Vivos Therapeutics raises $4.64 million through warrant exercise
-
Vivos Therapeutics opens affiliated sleep center in Auburn Hills
-
Vivos Therapeutics (VVOS) PT Lowered to $5.50 at Ascendiant Capital
-
Vivos Therapeutics (VVOS) Misses Q3 EPS by 1c
-
H.C. Wainwright Starts Vivos Therapeutics (VVOS) at Buy
-
Vivos Therapeutics (VVOS) Misses Q2 EPS by 16c
-
Vivos Therapeutics hires two executives to support expansion
-
Vivos Therapeutics (VVOS) Receives Medicare Approval for VidaSleep Oral Appliance
-
Vivos Therapeutics (VVOS) highlights positive trial results for treatment of OSA with Daytime-Nighttime Appliance
-
Vivos Therapeutics (VVOS) Completes Acquisition of The Sleep Center of Nevada
-
Alliance Global Partners Downgrades Vivos Therapeutics (VVOS) to Neutral
-
Vivos Therapeutics (VVOS) Misses Q1 EPS by 4c
-
Vivos Therapeutics (VVOS) Files $50M Mixed Shelf
-
Vivos Therapeutics (VVOS) Prices 709K Share Offering at $4.935/sh
-
Vivos Therapeutics (VVOS) Granted CPT Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices
-
Vivos Therapeutics (VVOS) Prices 1.36M Share Offering at $3.15/sh
-
Vivos Therapeutics (VVOS) Receives FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring
-
Vivos Therapeutics (VVOS) PT Raised to $6.60 at Ascendiant Capital
-
Vivos Therapeutics (VVOS) Misses Q2 EPS by 60c
-
Vivos Therapeutics (VVOS) Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model
-
Vivos Therapeutics (VVOS) Closes $7.5M ATM

